What is Urine Microalbumin (Microalbuminuria)?
Urine microalbumin, or microalbuminuria, is defined as urinary albumin excretion of 30-299 mg/g creatinine on a spot urine sample, representing the earliest detectable stage of kidney damage in diabetes and a powerful marker of systemic vascular dysfunction and cardiovascular risk. 1
Definition and Measurement Thresholds
The preferred screening method is the albumin-to-creatinine ratio (ACR) on a random spot urine sample, with first morning void specimens being optimal. 1
The classification of albumin excretion is:
- Normal (A1): <30 mg/g creatinine 1
- Microalbuminuria (A2): 30-299 mg/g creatinine 1
- Macroalbuminuria (A3): ≥300 mg/g creatinine 1
Diagnosis requires 2 out of 3 abnormal specimens collected over a 3-6 month period due to 40-50% day-to-day variability in albumin excretion. 1 This confirmation step is critical because single measurements can be misleading. 2
Clinical Significance: Beyond Just Kidney Disease
Cardiovascular Risk Marker
Microalbuminuria is a well-established marker of increased cardiovascular disease risk, predicting 2-4 fold increases in cardiovascular events and all-cause mortality independent of other risk factors. 1, 3 The presence of microalbuminuria indicates generalized endothelial dysfunction and vascular damage throughout the body, not just in the kidneys. 4, 5, 6
Kidney Disease Progression
In type 1 diabetes, 80% of patients with sustained microalbuminuria progress to overt nephropathy (macroalbuminuria) within 10-15 years without intervention. 1 In type 2 diabetes, 20-40% progress to macroalbuminuria and potential end-stage renal disease. 1, 7
Transient Causes to Exclude Before Diagnosis
Before confirming chronic microalbuminuria, exclude these transient elevations: 1
- Exercise within 24 hours 1, 2
- Urinary tract infection or fever 1, 2
- Marked hyperglycemia (>180 mg/dL) 1, 2
- Congestive heart failure 1, 2
- Marked hypertension 1, 2
- Hematuria or pyuria 1, 2
Screening Recommendations
Annual screening should begin at diagnosis in all type 2 diabetes patients and after 5 years duration in type 1 diabetes patients. 1, 4 The spot urine albumin-to-creatinine ratio is strongly recommended over 24-hour collections or timed specimens. 1
All hypertensive patients should also be screened for microalbuminuria to identify those at highest cardiovascular risk. 4, 2
Management Implications
Immediate Treatment Indications
Once persistent microalbuminuria is confirmed, initiate an ACE inhibitor or ARB immediately, regardless of baseline blood pressure. 4, 8 This recommendation carries Grade A evidence from the American Diabetes Association. 1, 8
Target blood pressure <130/80 mmHg in all patients with confirmed albuminuria. 4, 8
Additional Interventions
- Optimize glycemic control with HbA1c target <7% 1, 8
- Restrict dietary protein to approximately 0.8 g/kg/day 4, 8
- Provide intensive smoking cessation counseling 8
- Aggressive cardiovascular risk factor modification 1, 3
Common Pitfalls to Avoid
Do not wait for hypertension to develop before starting ACE inhibitor or ARB therapy—these agents are indicated for microalbuminuria even with normal blood pressure. 4, 8 This is a critical error that delays renoprotective and cardioprotective benefits.
Do not rely on a single ACR measurement—biological variability exceeds 20%, necessitating confirmation with multiple samples over 3-6 months. 1, 2
Do not use standard urine dipsticks—they lack sufficient sensitivity to detect microalbuminuria; specific albumin assays are required. 1, 2
Do not measure albumin concentration alone without creatinine correction—hydration status can produce false results. 2, 8
Monitoring After Diagnosis
Re-measure ACR at 6 months after therapy initiation to assess response. 8 If significant reduction occurs, transition to annual ACR testing. 8 If no improvement, reassess blood pressure control, medication adherence, and consider regimen modification. 8
Refer to nephrology when eGFR falls below 30 mL/min/1.73 m² or when there is rapidly increasing albuminuria, rapid eGFR decline, or uncertainty about kidney disease etiology. 1, 8